NUVISAN
↗Neu-Ulm, Germany
NUVISAN is a fully integrated contract research and development and manufacturing organization (CRO/CDMO) based in Germany and France. The company provides end-to-end solutions along the drug discovery and development value chain, supporting pharmaceutical, biotechnology, and venture capital partners from target identification to clinical trials and commercial supply.
Following its acquisition by ALS Limited in 2024, NUVISAN operates as a key division within the global testing leader, leveraging its expertise in drug discovery, preclinical testing, bioanalysis, clinical pharmacology, and pharmaceutical manufacturing to accelerate the development of next-generation medicines.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Founded:1979
Ownership:subsidiary
Status:acquired
FUNDING
Investors:ALS Limited
STOCK
Exchange:ASX
Ticker:ALQ
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery/Preclinical
Modalities:Small molecule, Antibody-drug conjugates, Peptides, PROTACs
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:ALS Limited
Acquired By:ALS Limited (2024-04-01)
Subsidiaries:Nuvisan ICB GmbH, Nuvisan Pharma Holding GmbH
Key Partnerships:Gates Foundation (Grant for contraceptive research), Servier, Merck, Takeda (CARE consortium)
COMPETITION
Position:Leader
Competitors:Nordic Bioscience, BioAgilytix, Solvias
LEADERSHIP
Key Executives:
Dietrich Bruchmann - Managing Director
LINKS
Website:nuvisan.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of NUVISAN and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NUVISAN. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.